Document
Keep your attention on the care encounter.
Record the conversation and clearly state your own findings and agreed actions.
Hysio Medical Oncology
AI Voice-Driven Reporting for medical oncologists
After a treatment discussion or evaluation, you say what was discussed. Hysio puts treatment schedule, side effects and the tumour board advice each in their place.
Spoken care information from your care encounter
Medical oncology
A structured report in your professional terminology
From care encounter to report
You work. Hysio documents.
Hysio turns spoken information into a report. Choose the report format for the conversation you are documenting.
AI assistants
Suited to your work.
- Hysio Oncology Intake
- Hysio Oncology Treatment Discussion
- Hysio Oncology Evaluation of Treatment and Side Effects
- Hysio Oncology Family Meeting
- Hysio Oncology SOAP Note
You stay in control of what gets saved.
In your workday
How Hysio fits into your workday
More attention for the conversation, less typing afterwards.
-
You document the conversation
State relevant information, your own findings and agreed actions aloud so you can find them in your report.
-
Hysio creates your report
The information appears under the headings of your chosen report format, so you can review each section.
-
You review and copy the report
Check names, facts and agreed actions. Edit the text where needed before using the report in your records.
Try it yourself
Experience what Hysio can mean for your work.
Try Hysio free for 14 days or schedule a personal demo.
- No credit card needed
- Cancel any month
- GDPR-compliant, data hosted in the EU
Profession
Hysio Medical Oncology
For your team
Share with a colleague
Quick answer Medical oncologist documentation for each care encounter 50 questions with cited sources
Quick answer
Treatment, side effects and tumour board
For systemic cancer treatment, with a dedicated place for schedule, side effects, tumour board advice and conversations with relatives.
Read how Hysio works in an oncology intake, a treatment discussion or an evaluation of side effects.
- What is voice-driven reporting for medical oncologists?
- After a treatment discussion or evaluation, as a medical oncologist you say what was discussed, and Hysio turns it into the report. This way of working is called voice-driven reporting or AI documentation. For medical oncology there are five documentation formats: Oncology Intake, Oncology Treatment Discussion, Oncology Evaluation of Treatment and Side Effects, Oncology Family Meeting and Oncology SOAP Note. [2] [3] [4] [5] [6]
- What stays tied to the source?
- In an oncology report, Hysio only includes what was said or supplied: history, information from the tumour board, results, the client's perspective, your assessment and the agreements. In AI reporting in oncology, that is the starting point. [1] [12]
- Who determines the content?
- You, as the medical oncologist. You check schedule, side effects and agreements before you save the report. [1] [10]
- Profile code 058
- Documentation formats 5 profession-specific documentation formats: Hysio Oncology Intake, Hysio Oncology Treatment Discussion, Hysio Oncology Evaluation of Treatment and Side Effects, Hysio Oncology Family Meeting, Hysio Oncology SOAP Note.
- Source focus oncology pathway, side effects experienced and shared discussion
- Record boundary you check schedule, side effects and agreements
Voice-driven reporting in medical oncology
Which documentation format do you choose when the treatment schedule is the reason for the conversation? #
If the treatment schedule already comes up when discussing the reason for the visit, Hysio Oncology Intake usually fits best: that format organises the reason for the contact, the medical history and the schedule discussed in a single first or current contact. If you discuss the schedule in depth, with regimen, cycle and alternatives, Hysio Oncology Treatment Discussion is a better fit. Both formats only include what you state explicitly; you add CTCAE information and performance status as soon as they come up in the conversation, without Hysio adding its own interpretation. [2] [3] [4] [5] [6] [1] [12]
How do performance status and tumour board advice each get their own place? #
Hysio keeps performance status and tumour board information in separate, recognisable sections of the report, so you do not have to read them mixed together. Performance status is included with the scale mentioned, such as ECOG, WHO or Karnofsky, and the date of the conversation in which it was discussed. Tumour board information gets its own heading with the conclusion and follow-up as formulated by the multidisciplinary team meeting. This keeps it clear which item comes from which moment, without Hysio merging the two into a single judgement. [2] [1] [11]
Where do side effects go in the record? #
You document side effects in the patient's own words: when the complaint started, how it developed and what effect it had on functioning. Hysio adds the professional observation separately, with source and moment, without mixing the two. Hysio only includes a CTCAE grade or cause if you state it out loud yourself; without that statement, the field stays empty. This keeps the record pathway traceable to the contact in which the side effect was discussed. [11] [1] [2]
How do you handle information from the tumour board with care? #
Hysio never automatically shares tumour board information beyond the contact in which you mention it; the report stays with you until you save or forward it yourself. Information from the multidisciplinary team meeting is subject to the same professional confidentiality as the rest of the record: share it only with a clear purpose and, where necessary, with the patient's consent. Hysio does not record a separate privacy rule per source category; the choice of who may see tumour board information stays with you and your institution. [9] [14] [1]
Do you pay for voice-driven reporting per treatment cycle? #
There is no separate rate for documenting CTCAE information: the Hysio price depends on the chosen plan, not on the type of content in a report. Starter, Pro and Unlimited are listed with current amounts on the pricing page, including the annual discount of two free months. Whether a contact is mainly about side effects, tumour board information or the treatment schedule makes no difference to the cost; the number of sessions within your plan is what counts, not the subject of the conversation. [7] [8]
When do you choose your own template for the treatment schedule? #
A template of your own for the treatment schedule fits when your institution uses a fixed, locally prescribed layout that differs from the standard format, for example for a specific protocol or registration requirement. Hysio Oncology Treatment Discussion covers the regular conversation about regimen, choice and follow-up; for an additional local form, you can copy the source-bound text and reorder it yourself. Always compare your own route with the source in the contact, so that CTCAE information and performance status do not become detached from where they came from. [1] [11] [12]
How do you check that the performance status matches what was said? #
Read the report back alongside what was actually said, and check whether the performance status mentioned, including scale and date, matches the conversation. Also compare tumour board information and the treatment schedule with their own source before you save; a fixed documentation format does not automatically make the content correct. If a score is missing or ambiguous, you correct or remove it yourself. This way the source check stays with you and not with the structure Hysio uses. [1] [12] [10]
How do you stay with the patient while you discuss side effects? #
Because Hysio records the conversation, you do not have to type at the same time while discussing side effects: you can listen, ask follow-up questions and keep eye contact. After the contact, you check the report and add what the patient said in their own words about the onset, course and consequences of the complaint. Performance status and tumour board information appear separately, so the report stays readable for the next colleague without the conversation itself being interrupted for administration. [1] [2] [11]
What does Hysio organise from the tumour board, and what do you assess? #
Where a loose notepad often mixes tumour board information with your own observations, Hysio keeps the two separate and traceable to the moment they were discussed. The format follows the contact itself instead of a fixed template you have to fill in beforehand. Side effects, the treatment schedule and performance status appear in a similar way, each with its own source. Hysio does not assess the substance of the tumour board information itself; as with a handwritten report, that interpretation stays with you and your team. [1] [2] [11]
How do you start with voice-driven reporting at a side-effect check-up? #
Start with one contact in which side effects and CTCAE information clearly come up, for example an evaluation consultation, and let Hysio process that one conversation. Check the report, compare it with what was said about performance status and tumour board information, and agree within your team who reads it back before you save. Only once this first trial is correct do you expand to the treatment schedule and other care encounters within medical oncology. [8] [9] [1]
Documentation formats for medical oncologists
Which format do you use for the first conversation in the oncology clinic? #
Hysio Oncology Intake fits the first or current contact in which the patient's reason for the visit, medical history and context are mapped out, often ahead of a decision about systemic anticancer therapy. The format organises what was said about previous treatment, tumour board information and expectations, with source and moment. For a detailed discussion of the treatment schedule itself, Hysio Oncology Treatment Discussion is a better fit; for a follow-up contact, the evaluation format fits. Diagnosis and indication stay with you as a medical oncologist. [2] [1] [12]
How do you record a discussion of the treatment plan? #
This format fits specifically the conversation in which you discuss the systemic anticancer therapy itself: regimen, treatment schedule, alternatives and the patient's questions. Hysio organises the reason for the conversation, the options discussed and the choice made, with side effects and tumour board information as separate source references where they are mentioned. If the contact is mainly a first introduction, the intake fits better; if it is a follow-up after the start of treatment, the evaluation format fits. The treatment decision stays with the medical oncologist. [3] [1] [12]
Which format fits the evaluation of treatment and side effects? #
This format is intended for the follow-up contact in which you discuss the effect of the systemic anticancer therapy and the side effects experienced. Hysio separates what the patient reports about CTCAE information and performance status from your own findings, and links both to the source and moment of this conversation. The format only includes tumour board information if it came up during this contact, not as a summary of earlier meetings. For the first contact or the treatment choice itself, the intake or treatment discussion format fits better. [4] [1] [12]
Which format fits a conversation with client and relatives about the next steps? #
Hysio Oncology Family Meeting fits a contact with relatives, separate from or alongside an intake, treatment discussion or evaluation about systemic anticancer therapy. The format records who was present, what role each person present had and what, with the patient's consent, was discussed about the treatment schedule and side effects. Tumour board information only appears if it was actually mentioned in this conversation. If explicit consent to share is missing, that stays visible in the report instead of being silently assumed. [5] [1] [12]
When is a SOAP note enough for a short check-up during the course of treatment? #
This format fits a short, recurring contact in which you prefer the fixed layout of Subjective, Objective, Assessment and Plan over an extensive intake or treatment report, for example an interim check-up during systemic anticancer therapy. Subjective contains what the patient reports about side effects and performance status, Objective your own findings, Assessment your interpretation and Plan the follow-up discussed. You place tumour board information under Assessment or Plan, strictly as discussed. For a full intake or treatment discussion, another format fits better. [6] [1] [12]
Which format fits a CTCAE grade: intake, treatment discussion or evaluation? #
CTCAE information usually belongs in Hysio Oncology Evaluation of Treatment and Side Effects, because that format is intended specifically to organise side effects experienced and their course. If you already mention CTCAE information during the intake or treatment discussion, Hysio includes it just as source-bound in that format; there is no separate CTCAE documentation format. What counts is therefore the moment the information comes up, not a fixed link between term and documentation format. Hysio only includes a grade or score if you mention it yourself. [1] [2] [12]
When do you choose an intake for a new treatment schedule? #
Hysio Oncology Intake is intended for situations where the treatment schedule is mapped out for the first time, together with the patient's broader reason for the visit and medical history. If the schedule itself is discussed in depth, with regimen, alternatives and the patient's choice, the treatment discussion fits better. If it is a follow-up once treatment is already under way, the evaluation format is intended for that follow-up. The three formats connect with one another, but each records a different moment in the pathway. [1] [2] [12]
What do you note about performance status after a result? #
After a results consultation, performance status should include the scale mentioned, such as ECOG, WHO or Karnofsky, the date of the conversation and how the patient describes their own functioning in relation to the result. Hysio links that information to the source: what the patient says themselves stays separate from your professional assessment. Tumour board information and the treatment schedule mentioned during the same conversation appear separately. Hysio does not itself establish a causal link between result and functioning. [1] [2] [12]
What do you put about side effects in a handover? #
In a handover, you note for each side effect where the information comes from: reported by the patient, observed by you or supplied through another contact. State onset, course and severity as they were actually discussed, together with the action already taken and what is still open. CTCAE information and performance status belong in it if they were mentioned in this contact. You check consent for sharing this information with the receiving colleague before you send the handover. [1] [2] [12]
How do you keep the tumour board advice apart from your own assessment? #
Hysio places tumour board information under its own heading, apart from what the patient says and from your own observations during the contact. This keeps it clear that a conclusion comes from the multidisciplinary team meeting and not from the current conversation. If information from the tumour board differs from what the patient now says about side effects or the treatment schedule, both readings stay side by side. You decide which source is decisive for the final text, not Hysio. [1] [2] [12]
Schedule, side effects and performance status
Does information from the tumour board belong in the history? #
Tumour board information only belongs in the medical history when you have actually discussed it with the patient during this contact, not as an automatic summary of an earlier meeting. Hysio includes the conclusion as you state it, noting that it concerns a tumour board or multidisciplinary team (MDT) discussion. The treatment schedule and side effects that come up in the same conversation get their own place alongside the medical history. If the link with this contact is missing, Hysio leaves the field empty instead of filling something in. [1] [12]
Who supplied the CTCAE data? #
For CTCAE information, Hysio always notes who supplied it: the patient, a relative who is present, your own observation or a referral letter read out during the contact. Hysio keeps that source role separate from your professional assessment, so it stays clear later what was reported and what was established. If the source of an item mentioned is missing, Hysio marks it as unclear instead of assuming a speaker. This keeps every CTCAE reference traceable to the moment it was mentioned. [1] [14] [12]
How do you note cycle dates and dosage in the treatment schedule? #
If you mention a cycle, dose or check-up date for the treatment schedule, Hysio records it exactly as spoken, including unit and measurement moment. Hysio does not perform any calculation or interpretation of that information; the professional meaning of the schedule stays with you. Performance status and tumour board information belonging to the same measurement moment appear as separate entries, so schedule and condition do not get mixed up. If a unit or date is missing, that stays visible as an open point instead of being filled in. [1] [12]
How do you link performance status to a result? #
Hysio places performance status next to the result it was discussed in relation to, with the date and source of both items, so the connection stays visible to the reader without Hysio establishing a cause. The treatment schedule and tumour board information that come up in the same conversation get their own line. If you state explicitly that a result affects the performance status, Hysio includes that statement as your assessment, not as its own conclusion. Without that statement, result and status stay side by side. [1] [12] [14]
Does Hysio assess CT or PET images? #
No, Hysio does not assess images and draws no conclusion about side effects based on a scan or photo. What Hysio does do is include the spoken account of an imaging study as you explain it, including source and date, and place it alongside performance status and tumour board information if you mention them in the same conversation. You may have a supplied radiology report included verbatim, but the medical interpretation of imaging stays with you and the reporting radiologist. [11] [10] [12]
Which terms do you use for tumour board information, such as TNM? #
Hysio does not replace your own professional term with a standard word: if you say tumour board, multidisciplinary team meeting or the abbreviation MDT, that term stays in the report as spoken. If your team consistently uses one term, it is advisable to keep using it in the contact as well, so colleagues understand the report without explanation. The treatment schedule and CTCAE information follow the same rule: the terminology comes from the conversation, not from a fixed Hysio word list. [1] [12]
How do you note CTCAE information that a relative mentions? #
If a relative reports something about CTCAE information, Hysio notes it explicitly as information from the relative, not as a statement by the patient. State the relationship to the patient and whether the patient was present for that part of the conversation. You record consent for taking this information into account and, where applicable, sharing it separately. Performance status and tumour board information mentioned by the relative get the same source reference, so it stays clear later who the item came from. [1] [14] [12]
What do you share with the team about the treatment schedule? #
For team use, a colleague mainly needs to know which discipline put forward the treatment schedule, what exactly was agreed and who takes the next step. Hysio makes that visible by showing the source of each item, without adding a summary of its own that goes beyond the conversation. Side effects and tumour board information belonging to the same discussion stay understandable for a colleague who was not present at the contact. The substantive coordination within the team therefore stays with you. [1] [2] [14]
Which case best shows how you record performance status? #
One example is a follow-up contact in which a patient receiving systemic anticancer therapy indicates that they still carry out daily activities largely independently, which you record as performance status ECOG 1. Hysio organises such a conversation into the reported complaint, your observation, the performance status mentioned with its scale, and the follow-up discussed, each with its source. Tumour board information is only added if it came up during this same contact. Such an example only serves to illustrate the format, not as a template for an actual diagnosis. [1] [12] [2]
What do you put in a handover about side effects? #
A source-bound handover about side effects contains only what was actually said in the contact: the complaint in the patient's words, the course and the action already taken, with source and date. Hysio does not add any interpretation or severity estimate of its own that was not stated; the receiving colleague draws the clinical conclusion. CTCAE information and performance status belong in it as soon as they were mentioned in this same conversation. This keeps the handover traceable to the moment the information was gathered. [11] [9] [14] [12]
Sources, privacy and boundaries in oncology care
Can Hysio infer a diagnosis from side effects? #
No, Hysio never makes a diagnosis and does not assess a side effect for severity or cause either. Hysio organises what you say yourself about the side effect, performance status and tumour board information, with source and moment, so you can read the conversation back clearly. You, as the medical oncologist, determine the medical meaning, including any CTCAE grade or the treatment schedule discussed. Where something remains uncertain, Hysio leaves it uncertain instead of suggesting a conclusion that was not stated. [10] [1] [12]
Who reviews the tumour board information before saving? #
You check tumour board information before a report is saved: Hysio organises the conclusion of the multidisciplinary team meeting as you state it, but makes no professional decision about the content. Compare the report with what was said during the conversation about the treatment schedule and side effects, and adjust whatever is not correct. You check CTCAE information in the same way before you save. The final text in the record remains your professional responsibility, not Hysio's. [1] [10] [14]
What do you do if CTCAE data are missing? #
If CTCAE information is missing from the conversation, Hysio marks that field as not discussed instead of filling in a value. The same applies to performance status, tumour board information or the treatment schedule: if you do not mention something, it stays empty in the report. You then decide whether to add it later, for example in a subsequent contact, or to deliberately leave it open. This prevents an empty item from being read by mistake as a negative finding. [1] [10] [12]
Do you use Hysio in an acute complication during treatment? #
No, Hysio is not intended for acute assessment of the treatment schedule and does not perform triage. In an acute situation, you first act according to the usual medical route; Hysio only records afterwards, source-bound, what was discussed and decided about the treatment schedule, side effects and performance status. You include tumour board information that came up during the acute handling as soon as there is time for it. The assessment of urgency and the corresponding action stay entirely with you as a medical oncologist. [10] [9] [12]
Who may receive the performance status from you? #
Who may receive information about performance status depends on the purpose and on the consent the patient has given for it; Hysio does not decide this itself. Before you share performance status, you check purpose, consent and recipient, just as with any other medical information. The treatment schedule and tumour board information you include in the same handover follow the same consent check. If there is no clear agreement about sharing, you only note what is needed within the current care encounter. [9] [14] [1]
Does Hysio make a plan for managing side effects? #
No, Hysio does not draw up a treatment plan and does not choose a next step for a side effect. Hysio lists what you discussed about the side effect, performance status and the related treatment schedule clearly, with source and moment, so you can easily find the plan you determined yourself. Tumour board information underlying that decision appears separately if you mention it. The substantive choice about continuing, adjusting or stopping stays with you as a medical oncologist. [10] [11] [12]
How do you leave doubt about the tumour board advice on record? #
If you yourself are unsure about tumour board information, for example because a conclusion is still provisional, Hysio leaves that uncertainty recognisable instead of making the text more definite than what you said. If you state explicitly that something is not yet final, Hysio includes that wording verbatim. You handle the treatment schedule and side effects you are unsure about in the same way: the uncertainty stays visible alongside the source. This lets you read back later what was already established at the time and what was still open. [1] [12] [10]
How do you record it when sources give a different CTCAE grade? #
If sources contradict each other about CTCAE information, for example because the patient reports something different from an earlier note, Hysio keeps both readings side by side with their own origin instead of choosing one. You handle performance status and tumour board information in the same way when sources differ. You assess which reading is leading for the final treatment schedule or follow-up; Hysio makes that difference visible, but does not decide which source is right. [1] [14] [12]
How do you note supportive medication alongside the treatment schedule? #
Hysio includes medication and the related treatment schedule verbatim as you say them, with name, dose, unit and time; Hysio does not perform any conversion or give dosing advice. Side effects you link to this medication appear with the same source and the moment of the conversation. Performance status and tumour board information that come up in the same contact get their own entry. Admin with AI does not change the medical assessment of the schedule in any way: that stays with you as the medical oncologist. [1] [12] [10]
How do you check the performance status before saving? #
Just before saving, compare the report with what was actually said about performance status, including the scale and date mentioned. At the same time, check whether the treatment schedule and side effects are correctly linked to their source and whether tumour board information has only been included when it was discussed in this contact. If a wording or item is not correct, you fix it yourself before the report becomes final. This final review stays with you, not with Hysio. [1] [9] [10] [14]
Introduction and daily use
What do you arrange in advance for a handover of the performance status? #
Before the handover, look at which performance status information the receiving colleague needs: the most recently mentioned scale, the date and the course discussed. Let Hysio prepare the source-bound report and agree within your team who reads it back before it is sent. You include the treatment schedule and tumour board information relevant to the follow-up separately, stating what is still open. This way you prepare a handover in which it stays clear to the recipient which contact each item comes from. [11] [9] [14] [2]
Which team agreement do you make about recording side effects? #
Agree within the team which headings and order you use for side effects, so a colleague can read a Hysio report without explanation. Also agree who checks the report before it goes into the record and how you handle CTCAE information that does not yet have a grade. A similar agreement is useful for performance status and tumour board information, with the same scale and terminology for the whole team. Hysio does not enforce a team agreement itself; you make it among yourselves. [1] [2] [11]
How do you start with a small trial around tumour board information? #
Start with one type of contact in which tumour board information comes up regularly, for example a follow-up contact after a multidisciplinary team meeting, and use Hysio for it a few times. Each time, check the report against what was said, and collect what you would like to adjust in the layout or terminology. Only expand to the treatment schedule, side effects and performance status in other care encounters when this first trial feels reliable. This keeps the trial period manageable and easy to evaluate. [8] [9] [1]
How do you align a report that includes CTCAE grades with your centre's agreements? #
Compare the Hysio report with the headings and layout your institution prescribes for CTCAE information, and rearrange the source-bound text into that local format where necessary. You adapt the treatment schedule and performance status in the same way, without losing the link to the source. Agree who in the team is authorised to check and approve that local layout. Tumour board information that does not fit the local template fields can stay separately under its own heading. [11] [1] [12]
How do you dictate an evaluation of side effects? #
For each side effect, state what the client experiences, since when and how severe it is. Then say separately which grade you give and what you agree about the schedule. That is voice-driven reporting: Hysio keeps the client's experience and your assessment apart. Performance status and tumour board information get their own place. [1] [12] [2]
How do you measure how much time the report on performance status takes? #
Measure yourself, within your own team, how much time it takes to check and save a report with performance status before and after using Hysio; a national or promised percentage does not reflect that. Also pay attention to time that shifts to checking tumour board information and the treatment schedule, not just to typing during the conversation itself. Count side effects that need attention during the final review separately. This gives you a picture that fits your practice. [1] [11] [8]
Which conditions apply during the trial period for an oncology team? #
The same trial conditions apply to documenting side effects as to the rest of Hysio: the current duration and conditions of the free trial are on the website, regardless of the subject of a contact. Side effects, CTCAE information and performance status are assessment points for the report structure's fit with your practice, before a switch to a paid plan. Tumour board information and the treatment schedule fall under the same conditions; there is no separate trial per subject. [8] [7] [9]
Where do you read the pricing and terms alongside your cancer centre's policy? #
For plans and trial conditions, go to Pricing. For agreements about health data and responsibilities, use Hysio's legal overview. Tumour board information has no plan price of its own. When assessing the platform, keep the conditions for data processing separate from the oncology content: treatment, professional conclusions and handover agreements are determined by the healthcare professionals involved, not by the pricing page. [7] [9] [10]
How do you record your own terms for CTCAE grades? #
Agree within your team which abbreviations and terms you use for CTCAE information, for example the version of the scale, and use them consistently during the contact; Hysio adopts the terminology as it is spoken. Record those agreements somewhere, so a new colleague recognises the same terms. The same approach applies to performance status, tumour board information and the treatment schedule. Hysio does not add any alternative or translated term of its own to what you said. [1] [11] [12]
Where do you start with a case with a changing treatment schedule? #
Split a complex case around the treatment schedule by contact: what was said during the intake, what during the treatment discussion and what during a later evaluation, each with its own source and date. Hysio does not automatically merge those contacts into one continuous story; you decide yourself how the different moments relate to one another. Side effects, performance status and tumour board information belonging to one of those contacts stay linked to that specific moment, without any additional conclusion that was not stated. [1] [12] [2] [10]
Sources
- 1 Hysio: Beroepsprofiel de medische oncologie (interne Hysio-documentatie) Document date: 2026-08-09 Accessed on 2026-08-31
- 2 Hysio: Hysio Oncologische Intake (interne Hysio-documentatie) Document date: 25 augustus 2026 Accessed on 2026-08-31
- 3 Hysio: Hysio Oncologische Behandelbespreking (interne Hysio-documentatie) Document date: 25 augustus 2026 Accessed on 2026-08-31
- 4 Hysio: Hysio Oncologische Evaluatie van Behandeling en Bijwerkingen (interne Hysio-documentatie) Document date: 25 augustus 2026 Accessed on 2026-08-31
- 5 Hysio: Hysio Oncologisch Familiegesprek (interne Hysio-documentatie) Document date: 25 augustus 2026 Accessed on 2026-08-31
- 6 Hysio: Hysio Oncologisch SOEP-Verslag (interne Hysio-documentatie) Document date: 26 augustus 2026 Accessed on 2026-08-31
- 7 Hysio: Actuele Hysio-prijzen (interne Hysio-documentatie) Document date: 2026-08-26 Accessed on 2026-08-31
- 8 Hysio: Actuele proefperiode (interne Hysio-documentatie) Document date: 2026-08-31 Accessed on 2026-08-31
- 9 Hysio: Hysio Privacyverklaring (interne Hysio-documentatie) Document date: 2026-07-16 Accessed on 2026-08-31
- 10 Hysio: Hysio Disclaimer (interne Hysio-documentatie) Document date: 2026-07-16 Accessed on 2026-08-31
- 11 Hysio: Hysio en medische dossiersystemen (interne Hysio-documentatie) Document date: 2026-07-16 Accessed on 2026-08-31
- 12 NVMO: NVMO, Differentiatie Medische Oncologie Document date: 2026-08-26 Accessed on 2026-08-26
- 13 Federatie Medisch Specialisten: Federatie Medisch Specialisten, Normeringsrapport van SONCOS Document date: 2026-08-26 Accessed on 2026-08-26
- 14 KNMG: KNMG, Omgaan met medische gegevens Document date: 2026-08-26 Accessed on 2026-08-26
- 15 NHG: NHG, Gegevensuitwisseling huisarts-specialist (HASP) Document date: 2026-08-26 Accessed on 2026-08-26
- 16 NCI: NCI, CTCAE / adverse event reporting Document date: 2026-08-26 Accessed on 2026-08-26
- 17 Zorginzicht: Zorginzicht, Meetinstrumenten oncologie Document date: 2026-08-26 Accessed on 2026-08-26
- 18 IKNL: IKNL, Nederlandse Kankerregistratie (NKR) Document date: 2026-08-26 Accessed on 2026-08-26
- 19 NZa: NZa, Medisch-specialistische zorg Document date: 2026-08-26 Accessed on 2026-08-26
- 20 KNMG: KNMG, Herregistratie-eisen medisch specialisten Document date: 2026-08-26 Accessed on 2026-08-26
- 21 Capaciteitsorgaan: Capaciteitsorgaan, Kernrapport Medisch en klinisch technologisch specialismen, Capaciteitsplan 2027-2030 Document date: 2026-08-26 Accessed on 2026-08-26
Hysio creates the report. You remain responsible for what you save in the record.